腾盛博药-B(02137)发布年度业绩，股东应占亏损2.23亿元 同比收窄56.19%

Core Viewpoint - The company reported a significant increase in revenue for the fiscal year ending December 31, 2025, primarily due to income from a licensing and technology transfer agreement with Health元 Group [1] Financial Performance - The company achieved revenue of RMB 18.605 million, compared to zero revenue in the same period last year [1] - The loss attributable to shareholders narrowed to RMB 222.3 million, a decrease of 56.19% year-on-year [1] - The loss per share was reported at RMB 0.31 [1]